Anti-RAPGEF3 monoclonal antibody
Pre-made anti-RAPGEF3 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to RAPGEF3/RAPGEF3 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T52489-Ab-1/ GM-Tg-hg-T52489-Ab-2 | Anti-Human RAPGEF3 monoclonal antibody | Human |
GM-Tg-rg-T52489-Ab-1/ GM-Tg-rg-T52489-Ab-2 | Anti-Rat RAPGEF3 monoclonal antibody | Rat |
GM-Tg-mg-T52489-Ab-1/ GM-Tg-mg-T52489-Ab-2 | Anti-Mouse RAPGEF3 monoclonal antibody | Mouse |
GM-Tg-cynog-T52489-Ab-1/ GM-Tg-cynog-T52489-Ab-2 | Anti-Cynomolgus/ Rhesus macaque RAPGEF3 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T52489-Ab-1/ GM-Tg-felg-T52489-Ab-2 | Anti-Feline RAPGEF3 monoclonal antibody | Feline |
GM-Tg-cang-T52489-Ab-1/ GM-Tg-cang-T52489-Ab-2 | Anti-Canine RAPGEF3 monoclonal antibody | Canine |
GM-Tg-bovg-T52489-Ab-1/ GM-Tg-bovg-T52489-Ab-2 | Anti-Bovine RAPGEF3 monoclonal antibody | Bovine |
GM-Tg-equg-T52489-Ab-1/ GM-Tg-equg-T52489-Ab-2 | Anti-Equine RAPGEF3 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T52489-Ab-1/ GM-Tg-hg-T52489-Ab-2; GM-Tg-rg-T52489-Ab-1/ GM-Tg-rg-T52489-Ab-2; GM-Tg-mg-T52489-Ab-1/ GM-Tg-mg-T52489-Ab-2; GM-Tg-cynog-T52489-Ab-1/ GM-Tg-cynog-T52489-Ab-2; GM-Tg-felg-T52489-Ab-1/ GM-Tg-felg-T52489-Ab-2; GM-Tg-cang-T52489-Ab-1/ GM-Tg-cang-T52489-Ab-2; GM-Tg-bovg-T52489-Ab-1/ GM-Tg-bovg-T52489-Ab-2; GM-Tg-equg-T52489-Ab-1/ GM-Tg-equg-T52489-Ab-2 |
Products Name | Anti-RAPGEF3 monoclonal antibody |
Format | mab |
Target Name | RAPGEF3 |
Protein Sub-location | Introcelluar Protein |
Category of antibody | Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
Tag | Fc |
Products description | Pre-made anti-RAPGEF3 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-T52489-Ag-1 | Recombinant multi-species RPGF3/ RAPGEF3/ CAMP-GEFI protein |
Target information
Target ID | GM-T52489 |
Target Name | RAPGEF3 |
Gene ID | 10411,223864,59326,703967,486591,101085387,535383,100050541 |
Gene Symbol and Synonyms | 2310016P22Rik,9330170P05Rik,bcm910,CAMP-GEFI,EPAC,EPAC1,HSU79275,RAPGEF3 |
Uniprot Accession | O95398,Q9Z1C8 |
Uniprot Entry Name | RPGF3_HUMAN,RPGF3_RAT |
Protein Sub-location | Introcelluar Protein |
Category | Therapeutics Target |
Disease | N/A |
Gene Ensembl | ENSG00000079337 |
Target Classification | N/A |
The target: RAPGEF3, gene name: RAPGEF3, also named as CAMP-GEFI, EPAC, EPAC1, HSU79275, bcm910. Enables guanyl-nucleotide exchange factor activity and protein domain specific binding activity. Involved in several processes, including positive regulation of protein modification process; regulation of actin cytoskeleton organization; and regulation of syncytium formation by plasma membrane fusion. Located in filopodium; lamellipodium; and microvillus. Colocalizes with cortical actin cytoskeleton and plasma membrane. Biomarker of congestive heart failure. [provided by Alliance of Genome Resources, Apr 2022].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.